Andrea Harkin

1.6k total citations
16 papers, 118 citations indexed

About

Andrea Harkin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Andrea Harkin has authored 16 papers receiving a total of 118 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Andrea Harkin's work include Colorectal Cancer Treatments and Studies (11 papers), Colorectal Cancer Surgical Treatments (8 papers) and Gastric Cancer Management and Outcomes (6 papers). Andrea Harkin is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Colorectal Cancer Surgical Treatments (8 papers) and Gastric Cancer Management and Outcomes (6 papers). Andrea Harkin collaborates with scholars based in United Kingdom, Australia and Denmark. Andrea Harkin's co-authors include Timothy Iveson, Mark Saunders, James Paul, Takeharu Yamanaka, Qian Shi, Valter Torri, Ioannis Boukovinas, Takayuki Yoshino, Alberto F. Sobrero and Roberto Labianca and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Andrea Harkin

15 papers receiving 116 citations

Peers

Countries citing papers authored by Andrea Harkin

Since Specialization

Citations

This map shows the geographic impact of Andrea Harkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Harkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Harkin more than expected).

Fields of papers citing papers by Andrea Harkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Harkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Harkin. The network helps show where Andrea Harkin may publish in the future.

Co-authorship network of co-authors of Andrea Harkin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Harkin. A scholar is included among the top collaborators of Andrea Harkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Harkin. Andrea Harkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer 2024 ·Cell Reports Medicine ·(unknown), Faiz Jabbar, (unknown), (unknown), (unknown), Andrea Harkin, Timothy Iveson, Mark Saunders, Rachel Kerr, (unknown), Noori Maka, Jennifer Hay, Joanne Edwards, Ian Tomlinson, Owen J. Sansom, Caroline Kelly, Francesco Pezzella, David Kerr, Alistair Easton, Enric Domingo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
2	The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial 2023 ·ESMO Open ·Agnieszka Lemańska, Andrea Harkin, Timothy Iveson, Caroline Kelly, Mark Saunders, Sara Faithfull	4
3	Clinical performance of Immunoscore in stage III colorectal cancer patients in the SCOT and IDEA-HORG cohorts. 2022 ·Journal of Clinical Oncology ·David N. Church, Owen J. Sansom, Noori Maka, Joanne Edwards, Karin Oien, Timothy Iveson, Mark Saunders, Ioannis Boukovinas, Ippokratis Messaritakis, (unknown), (unknown), Vassilis Georgoulias, Alboukadel Kassambara, Aurélie Catteau, Jérôme Galon, Laura Dempsey, Jennifer Hay, Caroline Kelly, (unknown), Andrea Harkin	2
4	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis 2021 ·Clinical Colorectal Cancer ·Catherine Hanna, (unknown), Andrew Briggs, Andrea Harkin, Caroline Kelly, John McQueen, Karen Allan, Sarah Pearson, Niels Henrik Holländer, Bengt Glimelius, Ramón Salazar, Eva Segelov, Mark Saunders, Timothy Iveson, Robert J. Jones, Kathleen Boyd	2
5	Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin. 2021 ·Journal of Clinical Oncology ·Elisa Fontana, Jeffrey P. Meyers, Alberto F. Sobrero, Timothy Iveson, Anthony F. Shields, Julien Taı̈eb, Takayuki Yoshino, Ioannis Souglakos, (unknown), Florian Lordick, Markus Moehler, Andrea Harkin, Roberto Labianca, Jeffrey A. Meyerhardt, Thierry André, Takeharu Yamanaka, Ioannis Boukovinas, Axel Grothey, Irit Ben‐Aharon, Qian Shi, (unknown)	1
6	Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer 2020 ·JNCI Cancer Spectrum ·Prunella Blinman, Andrew Martin, Michael Jefford, David Goldstein, David Boadle, (unknown), Niall C. Tebbutt, (unknown), Andrea Harkin, Eva Segelov, Andrew Haydon, Timothy Iveson, Martin R. Stockler	4
7	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer 2020 ·British Journal of Cancer ·(unknown), Antonia K. Roseweir, Kathryn A.F. Pennel, Hester C. van Wyk, Arfon Powell, Donald C. McMillan, Paul G. Horgan, Caroline Kelly, Jennifer Hay, Owen J. Sansom, Andrea Harkin, Campbell S.D. Roxburgh, Janet Graham, David N. Church, Ian Tomlinson, Mark Saunders, Timothy Iveson, Joanne Edwards, James H. Park	14
8	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer 2020 ·The Journal of Pathology Clinical Research ·Antonia K. Roseweir, James H. Park, Sanne ten Hoorn, Arfon Powell, (unknown), Campbell SD Roxburgh, Donald McMillan, Paul G. Horgan, Elizabeth J. Ryan, Kieran Sheahan, Louis Vermeulen, James Paul, Andrea Harkin, Janet Graham, Owen J. Sansom, David N. Church, Ian D. Tomlinson, Mark Saunders, Timothy Iveson, Joanne Edwards	12
9	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. 2020 ·Journal of Clinical Oncology ·Alberto F. Sobrero, Thierry André, Jeffrey A. Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino, (unknown), Jeffrey P. Meyers, Roberto Labianca, Mark Saunders, Déwi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Eiji Oki, Vassilis Georgoulias, Valter Torri, Andrea Harkin, Julien Taı̈eb, Anthony F. Shields, Qian Shi	27
10	Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). 2019 ·Journal of Clinical Oncology ·Timothy Iveson, Alberto F. Sobrero, Takayuki Yoshino, (unknown), Fang‐Shu Ou, (unknown), Qian Shi, Mark Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels Henrik Holländer, Valter Torri, Kentaro Yamazaki, Vassilis Georgoulias, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul	27
11	SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. 2018 ·Journal of Clinical Oncology ·Mark Saunders, James Paul, (unknown), Gordon Brown, Timothy Iveson, Rachel Kerr, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, James T. Cassidy, Louise Medley, Sherif Raouf, Mark Harrison, A. Brewster, Charlotte Rees, Richard Ellis, Anne Thomas, Mark Churn, Noori Maka	0
12	Updated results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer 2017 ·Annals of Oncology ·Timothy Iveson, Rachel Kerr, Mark Saunders, Niels Henrik Holländer, Josep Tabernero, Andrew Haydon, (unknown), Andrea Harkin, Claire Scudder, Kathleen Boyd, Ashita Waterston, Louise Medley, Carlene Wilson, Richard Ellis, Sharadah Essapen, A.S. Dhadda, Mark Harrison, Stephen Falk, (unknown), James Paul	1
13	Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. 2017 ·Journal of Clinical Oncology ·Timothy Iveson, Rachel Kerr, Mark Saunders, Niels Henrik Holländer, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Claire Scudder, Kathleen Boyd, Ashita Waterston, Louise Medley, Charles B. Wilson, Richard Ellis, Sharadah Essapen, A.S. Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, James Paul	6
14	SCOT: Short Course Oncology Therapy—A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. 2011 ·Journal of Clinical Oncology ·James Paul, Andrew Briggs, Andrea Harkin, Andrew Haydon, Timothy Iveson, Margaret Masterson, (unknown), J Cassidy	1
15	Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? 2011 ·Trials ·Kathleen Boyd, Andrew Briggs, James Paul, Timothy Iveson, (unknown), Andrea Harkin, Gaynor J. Bates, Laura E. Crotty Alexander, Jim Cassidy	7
16	Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study 2011 ·Trials ·James Paul, Timothy Iveson, Rachel Midgley, Andrea Harkin, (unknown), Laura E. Crotty Alexander, Jim Cassidy	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact